Business Context and Reporting Period
Brilliant Acquisition Corporation, a British Virgin Islands special purpose acquisition company, filed this Form 8-K on November 1, 2023, regarding its proposed business combination with Nukkleus Inc. The filing does not identify T3 Defense Inc.; the registrant named in the filing is Brilliant Acquisition Corporation.
Under the proposed transaction, Brilliant would redomicile from the British Virgin Islands to Delaware, after which BRIL Merger Sub, Inc. would merge with and into Nukkleus, with Nukkleus surviving as a wholly owned subsidiary of Brilliant.
Material Transaction Terms and Changes
- On November 1, 2023, the parties entered into Amendment No. 1 to the Amended and Restated Agreement and Plan of Merger.
- The Exchange Ratio was revised from 1:26.227 to 1:35.
- Closing Payment Shares issuable to existing Nukkleus common stockholders were reduced from 14,000,000 shares to 10,500,000 shares.
- The composition of the post-business-combination board of directors was revised.
Financial Metrics, Liquidity, and Capitalization
This Form 8-K does not provide current-period revenue, profit, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics. It also does not provide a clear updated pro forma ownership or capitalization table following the amendment.
Guidance, Outlook, Risks, and Contingencies
- Completion of the business combination remains subject to applicable conditions, including approval by Brilliant shareholders and Nukkleus stockholders, satisfaction of the minimum trust account amount after shareholder redemptions, and receipt of required governmental and regulatory approvals.
- The transaction may not close on time or at all, including if it is not completed by Brilliant’s business-combination deadline or an extension is not obtained.
- Additional risks include shareholder redemptions, Nasdaq listing requirements, potential legal proceedings, disruption to Nukkleus’s business and employee retention, regulatory changes, volatility in the securities, and the ability to execute post-closing business plans.
- The Form S-4 registration statement, proxy statement/prospectus, merger agreement, and related SEC filings contain additional transaction terms and risk factors.
- The filing is a Rule 425 written communication and is not an offer to sell securities or a solicitation of an offer or vote.
Most Important Facts to Verify
- Whether Brilliant and Nukkleus shareholders approve the proposed business combination.
- Whether the transaction satisfies the minimum trust-account condition after redemptions and obtains required regulatory approvals.
- The final Exchange Ratio, number of shares issued at closing, and post-transaction ownership percentages.
- The final composition of the post-combination board of directors.
- Whether the transaction closes before Brilliant’s business-combination deadline and whether Brilliant’s securities remain listed on Nasdaq.
- The definitive proxy statement/prospectus and any subsequent amendments filed with the SEC.